Trials / Completed
CompletedNCT03574389
A Study Assessing 13-valent Pneumococcal Conjugate Vaccine in Healthy Chinese Infants and Young Children
A PHASE 3 OPEN-LABEL TRIAL TO ASSESS THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN INFANTS AND YOUNG CHILDREN IN CHINA WHO ARE NAIVE TO PNEUMOCOCCAL VACCINATION
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 936 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 42 Days – 5 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to assess the safety and immunogenicity of 13-valent Pneumococcal conjugate vaccine in Chinese infant and young children.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | 13vPnC | suspension in prefilled syringe for intramuscular injection, 0.5 mL, only one dose |
| BIOLOGICAL | Hib | suspension in prefilled syringe for intramuscular injection, 0.5 mL, only one dose |
Timeline
- Start date
- 2018-06-23
- Primary completion
- 2021-08-23
- Completion
- 2023-10-13
- First posted
- 2018-07-02
- Last updated
- 2024-11-05
- Results posted
- 2024-04-26
Locations
2 sites across 1 country: China
Source: ClinicalTrials.gov record NCT03574389. Inclusion in this directory is not an endorsement.